The concept and application of antisense oligonucleotides

Diseases of the Colon and Rectum

Volumn 44, Issue 9, 2001, Pages 1241-1243

  Yacyshyn, Bruce R ^b   Crooke, Stanley T ^a  

^a ISIS PHARMACEUTICALS   (United States)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Alicaforsen ; Antisense; Crohn's disease; ICAM 1

Indexed keywords

ALICAFORSEN; ANTISENSE OLIGONUCLEOTIDE; DOUBLE STRANDED DNA; FOMIVIRSEN; INTERCELLULAR ADHESION MOLECULE 1;

ARTICLE; CLINICAL TRIAL; CROHN DISEASE; DNA HELIX; ENTERITIS; GENE THERAPY; HUMAN; INFECTION; INFLAMMATION; ONCOLOGY; PSORIASIS;

EID: 0034846897     PISSN: 00123706     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02234777     Document Type: Article

References (7)

1. Antisense technology part A
2. Antisense oligonucleotides as a tool for gene functionalization and target validation
3. Inhibition of splicing of wild-type and mutated luciferase-adenovirus pre-mRNAs by antisense oligonucleotides
4. Antisense inhibition of membrane-bound human interleukin-5 receptor-alpha chain does not affect soluble receptor expression and induces apoptosis in TF-1 cells
5. A review of issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides
6. Crohn's disease, ulcerative colitis and normal intestinal lymphocytes express integrins in a dissimilar pattern
7. A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease